SEARCH

SEARCH BY CITATION

References

  • 1
    Sallie R, Cohen AT, Tibbs CJ, Portmann BC, Rayner A, O'Grady JG, et al. Recurrence of hepatitis C following orthotopic liver transplantation: a polymerase chain reaction and histological study. J Hepatol 1994; 21: 536542.
  • 2
    Feray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 11371143.
  • 3
    Randhawa PS, Demetris AJ. Hepatitis C virus infection in liver allografts. Pathol Annu 1995; 2: 203226.
  • 4
    Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation [see comments]. N Engl J Med 1996; 334: 815820.
  • 5
    Greenson JK, Svoboda-Newman SM, Merion RM, Frank TS. Histologic progression of recurrent hepatitis C in liver transplant allografts. Am J Surg Pathol 1996; 20: 731738.
  • 6
    Johnson MW, Washburn WK, Freeman RB, FitzMaurice SE, Dienstag J, Basgoz N, et al. Hepatitis C viral infection in liver transplantation. Arch Surg 1996; 131: 284291.
  • 7
    Gayowski T, Singh N, Marino IR, Vargas H, Wagener M, Wannstedt C, et al. Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome. Transplantation 1997; 64: 422426.
  • 8
    Samuel D, Feray C, Bismuth H. HCV infection and liver transplantation. Acta Gastroenterol Belg 1997; 60: 214216.
  • 9
    Vierling JM, Villamil FG, Rojter SE, Camacho KB, Goldman DE. Morbidity and mortality of recurrent hepatitis C infection after orthotopic liver transplantation. J Viral Hepat 1997; 1: 117124.
  • 10
    Bizollon T, Adahm M, Ducerf C, Baulieux J, Trepo C. New approaches to treatment of recurrent hepatitis C virus following liver transplantation using ribavirin. Transplant Proc 1996; 28: 28422843.
  • 11
    Mazzaferro V, Tagger A, Schiavo M, Regalia E, Pulvirenti A, Ribero ML, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33: 13551357.
  • 12
    Gruener NH, Gerlach JT, Jung MC, Diepolder HM, Schirren CA, Zachoval R, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000; 181: 15281536.
  • 13
    Nelson DR, Marousis CG, Ohno T, Davis GL, Lau JY. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 1998; 28: 225230.
  • 14
    Koziel MJ, Dudley D, Wong JT, Dienstag J, Houghton M, Ralston R, Walker BD. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992; 149: 33393344.
  • 15
    Koziel MJ, Dudley D, Afdhal N, Choo QL, Houghton M, Ralston R, Walker BD. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol 1993; 67: 75227532.
  • 16
    Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo QL, et al. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995; 96: 23112321.
  • 17
    Koziel MJ, Walker BD. Characteristics of the intrahepatic cytotoxic T lymphocyte response in chronic hepatitis C virus infection. Springer Semin Immunopathol 1997; 19: 6983.
  • 18
    Rehermann B, Chang KM, McHutchinson J, Kokka R, Houghton M, Rice CM, Chisari FV. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 1996; 70: 70927102.
  • 19
    Cerny A, McHutchison JG, Pasquinelli C, Brown ME, Brothers MA, Grabscheid B, et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995; 95: 521530.
  • 20
    Chang KM, Thimme R, Melpolder JJ, Oldach D, Pemberton J, Moorhead-Loudis J, et al. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 2001; 33: 267276.
  • 21
    Ferrari C, Valli A, Galati L, Penna A, Scaccaglia P, Giuberti T, et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 1994; 19: 286295.
  • 22
    Hoffmann RM, Gunther C, Diepolder HM, Zachoval R, Eissner HJ, Forst H, et al. Hepatitis C virus infection as a possible risk factor for ductopenic rejection (vanishing bile duct syndrome) after liver transplantation. Transpl Int 1995; 8: 353359.
  • 23
    Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999; 117: 933941.
  • 24
    Schirren CA, Jung MC, Gerlach JT, Worzfeld T, Baretton G, Mamin M, et al. Liver-derived hepatitis C virus (HCV)-specific CD4+ T cells recognize multiple HCV-epitopes and produce interferon gamma. Hepatology 2000; 32: 597603.
  • 25
    Rosen HR, Miner C, Sasaki AW, Lewinsohn DM, Conrad AJ, Bakke A, et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology 2002; 35: 190198.
  • 26
    Rehermann B, Chang KM, McHutchison JG, Kokka R, Houghton M, Chisari FV. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 1996; 98: 14321440.
  • 27
    Schirren CA, Zachoval R, Gerlach JT, Ulsenheimer A, Gruener NH, Diepolder HM, et al. Antiviral treatment of recurrent hepatitis C virus (HCV) infection after liver transplantation: association of a strong, multispecific, and long-lasting CD4+ T cell response with HCV-elimination. J Hepatol 2003; 39: 397404.
  • 28
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696699.
  • 29
    Panel I, Demetris AJ, Batts KP, Dhillon AP, Ferrell L, Fung J, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658663.
  • 30
    Kita H, Moriyama T, Kaneko T, Harase I, Nomura M, Miura H, et al. HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein. Hepatology 1993; 18: 10391044.
  • 31
    Shirai M, Okada H, Nishioka M, Akatsuka T, Wychowski C, Houghten R, et al. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol 1994; 68: 33343342.
  • 32
    Battegay M, Fikes J, Di Bisceglie AM, Wentworth PA, Sette A, Celis E, et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 1995; 69: 24622470.
  • 33
    Kurokohchi K, Akatsuka T, Pendleton CD, Takamizawa A, Nishioka M, Battegay M, et al. Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region. J Virol 1996; 70: 232240.
  • 34
    Healey C, McAdam C, Plebanski M, Chapman R, Rosenberg W. Cytotoxic T lymphocyte epitopes in hepatitis C virus identified with HLA assembly assays [Abstract]. Gastroenterology 1996; 110: 1209A.
  • 35
    Wong DK, Dudley DD, Afdhal NH, Dienstag J, Rice CM, Wang L, et al. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol 1998; 160: 14791488.
  • 36
    Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74: 23912399.
  • 37
    elGhazali GE, Paulie S, Andersson G, Hansson Y, Holmquist G, Sun JB, et al. Number of interleukin-4- and interferon-gamma-secreting human T cells reactive with tetanus toxoid and the mycobacterial antigen PPD or phytohemagglutinin: distinct response profiles depending on the type of antigen used for activation. Eur J Immunol 1993; 23: 27402745.
  • 38
    Missale G, Cariani E, Lamonaca V, Ravaggi A, Rossini A, Bertoni R, et al. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients. Hepatology 1997; 26: 792797.
  • 39
    Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346355.
  • 40
    Zhang ZX, Milich DR, Peterson DL, Birkett A, Schvarcz R, Weiland O, Sallberg M. Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy. J Infect Dis 1997; 175: 12941301.
  • 41
    Chang KM, Gruener NH, Southwood S, Sidney J, Pape GR, Chisari FV, Sette A. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol 1999; 162: 11561164.
  • 42
    Starzl TE, Demetris AJ, Trucco M, Ramos H, Zeevi A, Rudert WA, et al. Systemic chimerism in human female recipients of male livers. Lancet 1992; 340: 876877.